Biolinq led a $100m Series C round in Alpha Wave Ventures.

Biolinq, a health technology, led a $100m Series C round in Alpha Wave Ventures, a global investment company, with participation from RiverVest Venture Partners, AXA IM Alts, LifeSci Venture Partners, M Ventures, Hikma Ventures, Aphelion Capital, Taisho Pharmaceutical and Features Capital. “This financing will bolster Biolinq’s commercial readiness efforts while we pursue regulatory approval for the first intradermal glucose sensor that incorporates activity and sleep information into a single wearable device. Our team has spent the last decade developing a biosensor platform designed to inspire healthier living by providing context around a person’s metabolic health,” Rich Yang, Biolinq CEO.